Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.
Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.
A cancer treatment comprises the administration of a pro-drug compound identified by an in silico candidate identification screening. The pro-drug candidates are selected from a data base and calculations are carried out on the association of the pro-drug candidates to form a complex with a metal ion and a proteasome active site. The pro-drug inhibits the active site of the proteasome in the presence of the metal ion and has little or no effect in the absence of the metal ion. The pro-drug can be: 3,4-dihydroxybenzoic acid; galloflavin; 2-[(carbamoylsulfanyl)acetyl]amino}benzoic acid; 6,7-Dihydroxycoumaranone; 3,6-bis(hydroxymethyl)pyridazin-4(1H)-one; and 4′,5,7-trihydroxyisoflavone, for binding with copper ion and proteasome.